Anastrozole
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Anastrozole: aromatase inhibitor → Neuroblastoma
One-Sentence Summary
Anastrozole is an aromatase inhibitor (an oral hormonal therapy) that is currently marketed in Canada. The TxGNN model predicts it may be effective for Neuroblastoma, with a score of 0.9953. There are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Neuroblastoma |
| TxGNN Prediction Score | 0.9953 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 18 of 19; dormant: 1) |
| Number of DINs | 19 (marketed: 18) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for anastrozole is not available in the data compiled for this report. Anastrozole is known as an aromatase inhibitor, a drug class that lowers oestrogen production.
No established mechanistic link between aromatase inhibition and neuroblastoma has been identified. Neuroblastoma is a paediatric tumour of neural-crest origin and is not classically driven by oestrogen. The high score is a computational prediction only. No trials or publications in the compiled data study anastrozole in neuroblastoma, so the prediction should be treated as a hypothesis to test, not as support for clinical use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
- Drug Interactions: The interaction screen returned 100 potential interacting drugs. All shown entries have an unclassified severity level. Examples include bupropion, omeprazole, pantoprazole, metformin, simvastatin, prednisone, morphine and acetylsalicylic acid. Their clinical significance needs pharmacist review.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no supporting clinical trials, no literature and no established mechanism, so the evidence level is L5. The drug is widely marketed in Canada, but that does not support its use in neuroblastoma.
To proceed, the following is needed:
- Preclinical studies (e.g. neuroblastoma cell-line or animal models) testing whether aromatase inhibition has any effect
- Mechanism of action data to assess whether oestrogen or aromatase pathways are relevant to neuroblastoma biology
- Health Canada package insert warnings and contraindications for the safety review
- Paediatric safety and dosing considerations, since neuroblastoma mainly affects young children
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.